Department of Microbiology and Biotechnology, Shoolini University, Solan, Himachal Pradesh, 173229, India.
Faculty of Applied Science and Biotechnology, Shoolini University, Solan, Himachal Pradesh, 173229, India.
Clin Transl Oncol. 2024 Jun;26(6):1300-1318. doi: 10.1007/s12094-023-03368-2. Epub 2024 Jan 20.
In recent years, cancer has become one of the primary causes of mortality, approximately 10 million deaths worldwide each year. The most advanced, chimeric antigen receptor (CAR) T cell immunotherapy has turned out as a promising treatment for cancer. CAR-T cell therapy involves the genetic modification of T cells obtained from the patient's blood, and infusion back to the patients. CAR-T cell immunotherapy has led to a significant improvement in the remission rates of hematological cancers. CAR-T cell therapy presently limited to hematological cancers, there are ongoing efforts to develop additional CAR constructs such as bispecific CAR, tandem CAR, inhibitory CAR, combined antigens, CRISPR gene-editing, and nanoparticle delivery. With these advancements, CAR-T cell therapy holds promise concerning potential to improve upon traditional cancer treatments such as chemotherapy and radiation while reducing associated toxicities. This review covers recent advances and advantages of CAR-T cell immunotherapy.
近年来，癌症已成为主要死亡原因之一，全球每年约有 1000 万人因此死亡。最先进的嵌合抗原受体（CAR）T 细胞免疫疗法已成为癌症治疗的一种有前途的方法。CAR-T 细胞疗法涉及对从患者血液中获得的 T 细胞进行基因修饰，然后再输注回患者体内。CAR-T 细胞免疫疗法已导致血液癌症的缓解率显著提高。CAR-T 细胞疗法目前仅限于血液癌症，目前正在努力开发其他 CAR 构建体，如双特异性 CAR、串联 CAR、抑制性 CAR、联合抗原、CRISPR 基因编辑和纳米颗粒递送。随着这些进展，CAR-T 细胞疗法有望改善传统癌症治疗方法，如化疗和放疗，同时减少相关毒性。本文综述了 CAR-T 细胞免疫疗法的最新进展和优势。
